Bli medlem
Bli medlem

Du är här


Weifa ASA : Record revenues in the fourth quarter

Oslo, 19 February 2016

Weifa ASA: Record revenues in the fourth quarter

· All time high revenues in fourth quarter 2015 of NOK
97.6 million (NOK 90.5 million)

· EBITDA margin of 22.6%

· Strong cash flow from operating activities

· Full-year revenues rose 5.6%

· Strong brands secured high market share in all
categories and segments of both channels

· Asan acquisition, adding the leading Norwegian intimate
care brand to the Weifa portfolio

· Weifa expects full-year 2016 organic revenue growth and
improved EBITDA margin

Weifa ASA (OSE: WEIFA) had record revenues in the fourth quarter 2015 with
increased sales in all categories. Total revenue for the quarter was NOK
97.6 million, representing an increase of 7.9% compared with the year earlier
period. Weifa maintained high market share in all key segments during the
quarter, and delivered continued good operations.

EBITDA was NOK 24.4 million, before NOK 2.4 million in the calculated cost of
employee options and costs in conjunction with the acquisition of Cederroth
AS and the Asan portfolio, corresponding to an adjusted EBITDA margin of 25%.

Total consumer health revenue for the year 2015 was NOK 332.5 million,
representing an increase of 5.6 percent from 2014. Full-year EBITDA came to
NOK 72.9 million before option- and other costs of NOK 7.3 million,
corresponding to an adjusted EBITDA margin of 22%.

"Weifa delivered revenue growth and improved EBITDA margin through 2015 while
at the same time becoming a pure consumer health company and in the fourth
quarter announcing the acquisition of the leading intimate care brand Asan.
We have extended our platform of flagship brands as we move into 2016 and
target continued organic growth and improved EBITDA margin", says CEO
Kathrine Gamborg Andreassen.

Weifa will give a presentation today at 08:30 CET at Felix Konferansesenter,
Bryggetorget 3, Oslo, Norway. CEO Kathrine Gamborg Andreassen and CFO Simen
Nyberg-Hansen will represent the company. The presentation will also be
webcast live and can be accessed directly from:

Please find the report and presentation for the fourth quarter enclosed. The
report and presentation will also be made available

For further information, please contact:

Kathrine Gamborg Andreassen


+47 95 17 86 80

Simen Nyberg-Hansen


+47 98 20 63 55

Weifa is Norway's leading consumer health company. We supply real value
through medicines, lifestyle products and solutions that address the
essential needs of consumers, customers and professional partners. Weifa was
founded in 1940 and now employs about 30 highly qualified people at our
headquarters in Oslo. The company has a strong position in Norway and is the
market leader in pain relief, with well-established brands such as Paracet
and Ibux. We are also present in other key areas such as dietary supplements
and treatment for colds and respiratory problems. Weifa is listed on the Oslo
Børs (ticker WEIFA). For further information, please visit:

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Weifa ASA fourth quarter report 2015
Weifa ASA fourth quarter presentation 2015


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Weifa ASA via Globenewswire


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.